Kedrion grows in North America as it completes acquisition of Prometic
Oct 18, 2021 |
CORPORATE
Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency
Kedrion Biopharma expands its commitment in Turkey
Oct 14, 2021 |
CORPORATE
Expansion plans revealed at Embassy reception in Ankara on October 14
4ID – Kedrion proud to support new App for patients with Immunodeficiencies
Oct 04, 2021 |
CORPORATE
Our company restates its long-standing and consistent collaboration with IPOPI
KIDCARES10, First Patient Treated in Pediatric PI Study
Jul 26, 2021 |
CORPORATE
Thirty patients aged 2 to 17yo to be enrolled over five European countries
Kedrion stronger in North America and further committed to rare diseases
Jun 25, 2021 |
CORPORATE
Agreement with Canadian-based Liminal BioSciences signed on June 22nd
Kedrion Biopharma supports the launch of “Nature Italy”
Oct 19, 2020 |
CORPORATE
The Company reaffirms and strengthens its commitment to research and innovation
Kedrion alongside AICE on the 50th Ann. of the first AICE Triennial Conference
Oct 07, 2020 |
CORPORATE
The company supports the reading of a scientific study on the role of Factor VIII in the protection of the joints
Kedrion announces the appointment of a new CEO
Oct 05, 2020 |
CORPORATE
Val Romberg from the USA, one of the most esteemed managers in the industry
KEDPLASMA GmbH changes its name to Kedrion Biopharma GmbH
Aug 31, 2020 |
CORPORATE
Further step towards an even stronger focus on patients in Europe
